Sorafenib (Bayer43-9006; Nexavar) can be a novel, modest molecular specific numerous tyrosine protein kinase inhibitors (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. Nexavar (Bayer43-9006; Nexavar) stops the proliferation of tumor by focusing on the Raf/MAPK/ERK signaling transduction pathway; in addition, it has distinguished anti-angiogenic activities attained by way of inhibiting the tyrosine kinase VEGR-2 and VEGFR-3 as well as PDGF receptor beta.
Recently, two important stage II clinical randomized, placebo-controlled trials are carried out in the West and Asia-pacific area. The outcomes from this two studies have obviously exhibited the survival benefit in making use of single-agent Nexavar in dealing with individuals with sophisticated hepatocellular carcinoma (HCC). The patients randomized to sorafenib arm had a median time to progression (TTP) of five level 5 months and general survival (OS) of ten stage 7 months inside the Western research, whilst time to progression (TTP) and overall survival (OS) had been two stage eight months and 6 point five months within the eastern trial, respectively.
Notably, the survival information through the patients enrolled within the Western trial virtually doubled these within the Eastern investigation. Even in the individuals treated with placebo, the overall survival of patients in the Western trial (for seven position 9 months) was still way far better than the individuals within the Eastern trial (lasting for four stage two months). What is the cause that produced the variations? This may attribute towards the reality that Asia centers generally attempt to enroll sufferers with poorer prognosis.[1]
References:
[1] Most cancers Res. 2004 Oct 1;64(19):7099-109.
没有评论:
发表评论